Brez internetne povezave — prikazana je shranjena različica strani.

Trevi Therapeutic…

USUSD
← Na filter delnic

Trevi Therapeutics Inc (US:TRVI) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 1. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
trevitherapeutics.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sedež
NEW HAVEN, United States
Izvršni direktor
Jennifer L. Good
Zaposleni
34
Delnice v obtoku
142.48 mio. na dan 2026-07-31
Prosto prenosljive delnice
118.32 mio.
Tržna kapitalizacija
1.92 mrd. USD
Notranje osebe
0.63%
Institucionalni vlagatelji
107.73%
Panoga (SIC)
Pharmaceutical Preparations
FCF
−52.9 mio. USD
Dolg
0
Dobiček in FCF — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Borze in oznake

BorzaOznakaValutaCenaVrsta
US USA StocksTRVIUSD12.825 -2.40%navadne delnice

Cena v 3 mesecih

US:TRVI · USD
dan rasti dan padcaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Novice ta teden

Novic s spletnega mesta podjetja še ni.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
NEA Management Company,…9.28%13.22 mio.2026-06-30
FMR, LLC8.82%12.56 mio.2026-06-30
Blackrock Inc.7.83%11.16 mio.2026-06-30
Frazier Life Sciences Ma…6.98%9.94 mio.2026-06-30
Wellington Management Gr…3.99%5.68 mio.2026-06-30
Vanguard Capital Managem…3.88%5.53 mio.2026-06-30
Vivo Capital, LLC3.58%5.09 mio.2026-06-30
Woodline Partners LP2.86%4.08 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.84%4.05 mio.2026-06-30
Vestal Point Capital, LP2.18%3.1 mio.2026-06-30
MPM Bioimpact LLC2.16%3.07 mio.2026-06-30
iShares Trust-iShares Ru…1.91%2.72 mio.2026-08-31
MUTUAL FUND SERIES TRUST…1.87%2.66 mio.2026-06-30
Fidelity Select Portfoli…1.67%2.37 mio.2026-07-31
Fidelity Securities Fund…1.37%1.95 mio.2026-07-31
VANGUARD INDEX FUNDS-Van…0.95%1.35 mio.2026-06-30
Fidelity Salem Street Tr…0.82%1.17 mio.2026-07-31
Fidelity Mt. Vernon Stre…0.73%1.04 mio.2026-07-31
AB CAP FUND, INC.-AB Sma…0.72%1.03 mio.2026-07-31
iShares Trust-iShares Ru…0.7%996 8572026-08-31
SCIASCIA THOMAS R (Offic…≈0.16%221 3732025-03-25
GOOD JENNIFER L (Chief E…≈0.15%213 3132025-03-21
BASKETT FOREST (Benefici…——2025-04-17
BEHBAHANI ALI (Beneficia…——2025-04-17
CHANG CARMEN (Beneficial…——2025-04-17
FLORENCE ANTHONY A JR (B…——2025-04-17
MAKHZOUMI MOHAMAD (Benef…——2025-04-17
NEW ENTERPRISE ASSOCIATE…——2025-04-17
SANDELL SCOTT D (Benefic…——2025-04-17
WALKER PAUL EDWARD (Bene…——2025-04-17